How many 8-K filings has Phio Pharmaceuticals Corp. filed?

Phio Pharmaceuticals Corp. (PHIO) has 36 8-K (Current Event Report) filings on record, spanning Jan 2024 to Apr 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Phio Pharmaceuticals Corp. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Phio Pharmaceuticals Corp. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Phio Pharmaceuticals Corp. (PHIO) — 8-K Filings

All 8-K filings from Phio Pharmaceuticals Corp.. Browse 36 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (36)

Phio Pharmaceuticals Files 8-K for Material Agreement — Apr 8, 2026 Risk: medium
Phio Pharmaceuticals Corp. filed an 8-K on April 8, 2026, to report the entry into a material definitive agreement. The filing includes financial statements and
Phio Pharmaceuticals Files 8-K — Mar 30, 2026 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on March 30, 2026, to report other events. The filing does not contain specific financial figures or new material agreem
8-K Filing — Dec 23, 2025
8-K Filing — Nov 25, 2025
Phio Pharmaceuticals Corp. Files 8-K — Nov 6, 2025 Risk: medium
Phio Pharmaceuticals Corp. announced on November 3, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales
Phio Pharmaceuticals Files 8-K — Nov 3, 2025 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on November 3, 2025, reporting on other events and financial statements. The company, formerly known as RXi Pharmaceutic
Phio Pharmaceuticals Corp. Files 8-K on Officer/Director Changes — Oct 31, 2025 Risk: medium
Phio Pharmaceuticals Corp. filed an 8-K on October 31, 2025, reporting on the departure of directors or certain officers, the election of directors, the appoint
Phio Pharmaceuticals Corp. Announces Corporate Governance Changes — Sep 15, 2025 Risk: medium
Phio Pharmaceuticals Corp. announced on September 11, 2025, a series of significant corporate actions. These include the departure of certain officers and direc
Phio Pharmaceuticals Files 8-K — Sep 3, 2025 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on September 3, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as R
Phio Pharmaceuticals Corp. Files 8-K with Material Agreements — Jul 30, 2025 Risk: medium
Phio Pharmaceuticals Corp. entered into a Material Definitive Agreement on July 25, 2025. The company also reported on unregistered sales of equity securities a
Phio Pharmaceuticals Files 8-K — Jul 25, 2025 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on July 25, 2025, reporting other events and financial statements. The company, formerly known as RXi Pharmaceuticals Co
Phio Pharmaceuticals Corp. Files 8-K — Jul 7, 2025 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on July 7, 2025, reporting "Other Events." The filing indicates the company's principal executive offices are located at
Phio Pharmaceuticals Files 8-K — Jun 26, 2025 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on June 26, 2025, reporting on events as of June 25, 2025. The filing is categorized under 'Other Events' and 'Financial
Phio Pharmaceuticals Corp. Announces Executive and Director Changes — Jun 12, 2025 Risk: medium
Phio Pharmaceuticals Corp. announced on June 6, 2025, changes in its executive and director roles. The company filed an 8-K report detailing the departure of ce
Phio Pharmaceuticals Corp. Files 8-K — May 7, 2025 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on May 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing indicates the company was f
Phio Pharmaceuticals Changes Auditors — Apr 22, 2025 Risk: low
Phio Pharmaceuticals Corp. announced on April 17, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered pub
Phio Pharmaceuticals Files 8-K — Apr 9, 2025 Risk: low
On April 9, 2025, Phio Pharmaceuticals Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicati
Phio Pharmaceuticals Appoints New Chief Medical Officer — Feb 20, 2025 Risk: medium
Phio Pharmaceuticals Corp. announced on February 19, 2025, the appointment of Dr. Michael H. Chang as Chief Medical Officer. Dr. Chang brings extensive experien
Phio Pharmaceuticals Corp. Files 8-K with Material Agreements — Jan 17, 2025 Risk: medium
Phio Pharmaceuticals Corp. announced on January 16, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sales
Phio Pharmaceuticals Files 8-K: Material Agreement, Equity Sales — Jan 15, 2025 Risk: medium
On January 14, 2025, Phio Pharmaceuticals Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securiti
Phio Pharmaceuticals Corp. Files 8-K — Jan 14, 2025 Risk: medium
On January 13, 2025, Phio Pharmaceuticals Corp. entered into a material definitive agreement. The company also reported other events and filed financial stateme
Phio Pharmaceuticals Files 8-K — Jan 13, 2025 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on January 13, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specif
Phio Pharmaceuticals Corp. Files 8-K: Material Agreement & Equity Sales — Dec 26, 2024 Risk: medium
Phio Pharmaceuticals Corp. announced on December 23, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales
Phio Pharmaceuticals Corp. Files 8-K: Material Agreement & Equity Sales — Dec 20, 2024 Risk: medium
On December 19, 2024, Phio Pharmaceuticals Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securit
Phio Pharmaceuticals Files 8-K — Dec 19, 2024 Risk: low
On December 18, 2024, Phio Pharmaceuticals Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indi
Phio Pharmaceuticals Files 8-K — Nov 7, 2024 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on November 7, 2024, reporting other events and financial statements. The company, formerly known as RXi Pharmaceuticals
Phio Pharmaceuticals Corp. Board Changes and Officer Compensation — Aug 1, 2024 Risk: medium
Phio Pharmaceuticals Corp. announced on July 15, 2024, a change in its board of directors. Specifically, Dr. Michael J. Yudell has been appointed as a new direc
Phio Pharmaceuticals to be Acquired by 03 Life Sciences — Jul 24, 2024 Risk: medium
Phio Pharmaceuticals Corp. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is ex
Phio Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — Jul 12, 2024 Risk: medium
On July 11, 2024, Phio Pharmaceuticals Corp. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
Phio Pharmaceuticals Terminates 03 Life Sciences License — Jul 5, 2024 Risk: medium
Phio Pharmaceuticals Corp. announced on July 3, 2024, the termination of its exclusive license agreement with 03 Life Sciences for the development and commercia
Phio Pharmaceuticals Files 8-K — Jul 2, 2024 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on July 2, 2024, reporting on events that occurred on July 1, 2024. The filing indicates material modifications to the r
Phio Pharmaceuticals to be Acquired by Fulcrum Therapeutics — Jun 21, 2024 Risk: medium
Phio Pharmaceuticals Corp. announced on June 17, 2024, that it has entered into a definitive agreement to be acquired by Fulcrum Therapeutics, Inc. The transact
Phio Pharmaceuticals to be Acquired by 03 Life Sciences — May 28, 2024 Risk: medium
Phio Pharmaceuticals Corp. announced on May 28, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is exp
Phio Pharmaceuticals Corp. Files 8-K with Material Agreement — May 17, 2024 Risk: medium
On May 16, 2024, Phio Pharmaceuticals Corp. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The compa
Phio Pharmaceuticals Files 8-K on Financials — Apr 2, 2024 Risk: low
Phio Pharmaceuticals Corp. filed an 8-K on April 2, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
PHIO Receives Nasdaq Delisting Notice for Bid Price Non-Compliance — Jan 26, 2024
Phio Pharmaceuticals Corp. (PHIO) announced on January 24, 2024, that it received a delisting notice from The Nasdaq Capital Market because its common stock fai

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX